Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art Review.

Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.

JACC. CardioOncology. 2024 Nov 19*** epublish ***

Darryl P Leong, Avirup Guha, Alicia K Morgans, Tamim Niazi, Jehonathan H Pinthus

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Cardio-Oncology Program, Georgia Cancer Center at Augusta University, Augusta, Georgia, USA., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, Quebec, Canada., Division of Urology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.